(AOF) – Biosynex cedes 0.3% to 21.18 euros while Theradiag jumps 42% to 2.5 euros. This morning, Biosynex announced that it held 18.82% of the capital and 18.89% of the voting rights of Theradiag. The test maker has acquired shares of the company specializing in in vitro diagnostics in the market. He also participated in the capital increase with maintenance of the preferential subscription rights of Theradiag shareholders for an amount of 5.3 million euros which closed on November 24, 2021.
Last week, as part of the strategic strengthening of its molecular biology offering, Biosynexa signed a firm offer letter to acquire the human health business line of the company Enalees.
This acquisition would relate in particular to a solution of rapid molecular diagnostic tests using an isothermal amplification method that can be used to identify certain infectious diseases.
In the first half of 2021, Biosynex achieved a turnover of 225.2 million euros, more than 5 times that of the first half of the previous year.
As announced, growth benefited from the great success of the entire range of Covid-19 tests marketed by the group to detect and better prevent this infection.
©
AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.
